ENVB

ENVB

USD

Enveric Biosciences Inc. Common Stock

$5.700-0.400 (-6.557%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$6.100

最高价

$6.645

最低价

$5.520

成交量

0.25M

公司基本面

市值

3.0M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

0.07M

交易所

NCM

货币

USD

52周价格范围

最低价 $5.52当前价 $5.700最高价 $1444.5

相关新闻

BusinessWire

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric expects to file Investigational New Drug application for EB-003 in early 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic

查看更多
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
BusinessWire

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that

查看更多
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
BusinessWire

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or

查看更多
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
BusinessWire

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or

查看更多
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications